Clinical Trials Logo
NCT number NCT02124668
Study type Interventional
Source Astellas Pharma Inc
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 30, 2014
Completion date July 3, 2017

Clinical Trial Summary

The purpose of this study is to monitor the safety of enzalutamide in patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03177759 - Living With Prostate Cancer (LPC) N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data N/A
Not yet recruiting NCT03160365 - Innovative Planning and Guidance System for Prostate Focal Brachytherapy N/A
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A
Active, not recruiting NCT00779168 - White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy Phase 1
Recruiting NCT01990196 - Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer Phase 2
Recruiting NCT02766543 - Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer Phase 2
Not yet recruiting NCT02766478 - Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer Phase 2
Not yet recruiting NCT03157947 - Culturally Tailored Decision Aid for Hispanic Patients Diagnosed With Prostate Cancer N/A
Recruiting NCT02747342 - A Phase 1 Trial of SHR3680 in Prostate Cancer as Monotherapy Phase 1
Recruiting NCT02543255 - Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) Phase 2
Recruiting NCT02906241 - PACCT: Partnering Around Cancer Clinical Trials N/A
Recruiting NCT02886598 - Safety and Efficacy of Firmagon® (Degarelix) for Injection N/A
Recruiting NCT02916537 - A Phase 1 Trial for Safety and Imaging Evaluation of CTT1057, a Small Molecule Inhibitor of Prostate Specific Membrane Antigen (PSMA) Phase 1
Recruiting NCT02911922 - Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer N/A
Recruiting NCT02918357 - Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence Phase 2/Phase 3
Recruiting NCT02766686 - Preference-based Comparative Study on Definitive Radiotherapy of Prostate Cancer With Protons N/A
Recruiting NCT02919111 - Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients Phase 2/Phase 3
Enrolling by invitation NCT02840552 - The Safety and Efficacy of 18F-Fluoromethylcholine (18F-FCH) PET/CT in Prostate Cancer Phase 3
Not yet recruiting NCT02816840 - PET-CT/MRI in the Radiotherapy for Prostate Cancer Phase 1/Phase 2